Publications for Harry Davis, PhD

  1. Foody J.M., Toth P.P., Tershakovec A.M., Musliner T., Tomassini J.E., Lowe R.S., Neff D.R., Davis H.R.: Efficacy and safety of ezetimibe plus atorvastatin therapy. Clinical Lipidology 9(4): 441-470, 2014
  2. Hentze H., Jensen K.K., Chia S.M., Johnd D.G., Shaw R.J., Davis H.R. , Shih S.J.,Wong K.K.: Inverse relationship between LDL cholesterol and PCSK9 plasma levels in dyslipidemic cynomolgus monkeys: effects of LDL lowering by ezetimibe in the absence of statins. Atherosclerosis 231:84-90, 2013
  3. Davis H.R. , Tershakovec A.M., Tomassini J.E., Musliner T.: Intestinal sterol transporters and cholesterol absorption inhibition. Current Opinion in Lipidology 2011 Dec; 22(6):467-78.
  4. Ason B., Tep S., Davis H.R. , Xu Y., Tetzloff G., Galinski B., Soriano F., Dubinina N., Zhu L., Stefanni A., Wong K.K., Tadin-Strapps M., Bartz S.R., Hubbard B., Ranalletta M., Sachs A.B., Flanagan W.M., Strack A., Kuklin N.A.: Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9 J Lipid Res. 52(4):679-87, 2011.
  5. Tremblay, A.J., Lamarche, B., Lemelin, V., Hoos, L., Benjannet, S., Seidah, N.G., Davis H.R. , Couture, P. Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J. Lipid Res. 52: 558-565, 2011.
  6. Davis H.R. , Lowe R.S., Neff D.R.: Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis 215: 266-278, 2011.
  7. Burnett D.A., Davis H.R. : Atherosclerosis I: LDL Cholesterol Lowering. Burger’s Medicinal Chemistry, Drug Discovery and Development. Pages 303-330, 2010.
  8. Davis H.R. , Halleck M.: Ezetimibe Mechanism of action update and recent controversies. The Year in Lipid Disorders Volume 2, Editor Peter P. Toth, Chapter 5, pages 81-96, 2010.
  9. Vassileva G., Hu W., Hoos L., Tetzloff G., Yang S., Liu L., Kang L., Davis H.R. , Hedrick J.A., Lan H., Kowalski T., Gustafson, E.L.: Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. J. Endocrinology 205: 225-232, 2010.
  10. LanH., Pang L., Smith M.M., Levitan D., Ding W., Li Liu, Shan L., Shah V.V., Laverty M., Arreaza G., Zhang Q., Murgolo N.J., Hernandez M., Green J.R., GustafsonE.L., Bayne M.L., Davis H.R. , HedrickJ.A.: Proprotein convertase subtilisin/kexin Type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells. J. Cell. Physiol. 224 (1) 273-281, 2010.
  11. Halleck M., Davis H.R. , Kirschmeier P.,LevitanD. , Snyder R.D., Treinen K., MacDonald J.S.: An Assessment of the Carcinogenic Potential of Ezetimibe Using Nonclinical Data in a Weight-of-Evidence Approach. Toxicology 258: 116-130, 2009.
  12. Davis H.R. , Altmann S.W.: Niemann-Pick C1 Like 1 (NPC1L1) an Intestinal Sterol Transporter. (Review) Biochimica et Biophysica Acta 1791: 679-683, 2009.
  13. LanH., HoosL.M., Li Liu1, TetzloffG., HuW., AbbondanzoS.J., VassilevaG., GustafsonE.L., HedrickJ.A., Davis H.R. : Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 57: 2999-3006, 2008.
  14. Davis, H.R. , Murgolo, N.J,, Graziano MP.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. Comment Letter. N Engl J Med. 359(5): 531, 2008.
  15. Davis H.R. , Basso F., Hoos L.M., Tetzloff G., Lally S.M., Altmann S.W.: Cholesterol homeostasis by the intestine: Lessons from Niemann-Pick C1 Like 1 (NPC1L1). Atherosclerosis Supplements 9:77-81, 2008.
  16. Zheng, S., Hoos, L., Cook, J., Tetzloff, G., Davis Jr. , H., van Heek, M., Hwa, J.J.: Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharm 584: 118-124, 2008.
  17. Davis, H.R. , Veltri, E.P.: Zetia: Inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. (Review) Journal of Atherosclerosis and Thrombosis (Japan) 14 (3): 99-108, 2007.
  18. Davis, H.R. , Hoos, L.M., Tetzloff, G., Maguire, M., Zhu, L., Graziano, M.P., Altmann, S.W.: Deficency of Niemann-Pick C1 Like 1 (NPC1L1) prevents atherosclerosis in apo E -/- mice. Arterioscler. Thromb. Vasc. Biol. 27:841-849, 2007.
  19. Hawes, B.E., O’NeillK.A., Yao, X., Crona, J.H., Davis, H.R. , Graziano, M.P., Altmann, S.W. In vivo reponsiveness to ezetimibe correlates with NPC1L1 binding affinity: Comparison of multiple species NPC1L1 orthologs. Mol Pharmacol. 71(1):19-29, 2007.
  20. Vassileva, G., Golovko, A., Markowitz, L., Abbondanzo, S.J., Zeng, M., Yang, S., Hoos, L., Tetzloff, G., Levitan, D., Murgolo, N.J., Keane, K., Davis, H.R. , Hedrick, J., Gustafson, E.L.: Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. BiochemJ. 398(3):423-30, 2006.
  21. Garcia-Calvo, M., Lisnock, J., Bull, H.G., Hawes, B.E., Burnett, D.A., Braun, M.P., Crona, J.H., Davis, H.R. , Dean, D.C., Detmers, P.A., Graziano, M.P., Hughes, M., MacIntyre, D.E., Ogawa, A., O’Neill K.A., Iyer, S.N., Shevell, D.E., Smith, M.M., Tang, Y.S., Ujjainwalla, F., Altmann, S.W., Chapman, K.T., Thornberry, N.A.: The target of ezetimibe is Niemann-Pick C1 Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA 102 (23): 8132-8137, 2005.
  22. Kowalski, T.J., Spar, B.D., Markowitz, L., Maguire, M., Golovko, A., Yang, S., Farley, C., Cook, J.A., Tetzloff, G., Hoos, L., Del Vecchio, R.A., Kazadoba, T.M., McCool, M.F., Hwa, J.J., Hyde, L.A., Davis, H., Vassileva, G., Hedrick, J.A., Gustafson, E.L.: Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice. J. of Endocrinology 185: 151-164, 2005.
  23. IyerS.N., Yao, X., Crona, J.H., Hoos, L.M., Tetzloff, G., Davis, H.R. , Graziano, M.P., Altmann, S.W.: Characterization of the putative and recombinant rat sterol transporter Niemann-Pick C1 Like 1 (NPC1L1) protein. Biochimica et Biophysica Acta (General Subjects) 1722 (3): 282-292, 2005.
  24. HarryR.Davis, Li-ji Zhu, LizbethM.Hoos, GlenTetzloff, MaureenMaguire, JianjunLiu, Xiaorui Yao, SaiPrasadN.Iyer, My-Hanh Lam, ErikG.Lund, PatriciaA.Detmers, MichaelP.Graziano, and ScottW. Altmann, Niemann-pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole body cholesterol homeostasis. J.Biol.Chem. 279 (32): 33586-33592, 2004.
  25. Altmann, S.W., Davis, H.R. , Zhu, L., Yao, X., Hoos, L.M., Tetzloff, G., IyerS.N., Maguire, M., Golovko, A., Zeng, M., Wang, L., Murgolo, N., Graziano, M.P.: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 303: 1201-1204, 2004.
  26. Davis HR . Ezetimibe: First in a new class of cholesterol absorption inhibitors. International Congress Series, Atherosclerosis XIII. Proceedings of the 13th International Atherosclerosis Symposium, Edited by Y.Matsuzawa, T.Kita, R.Nagai, and T. Teramoto, Volume 1262, pp 243-246, May 2004.
  27. Elner, S.G., Elner V.M., Kindzelskii A.L., HorinoK., Davis, H.R. , Todd R.F., GlagovS., Petty H.R.: Human RPE cell lysis of extracellular matrix: functional urokinase plasminogen activator receptor (uPAR), collagenase and elastase. Experimental Eye Research 76: 585-595, 2003.
  28. van Heek, M., Farley, C., Compton, D.S., Hoos, L., Torhan, A.S., Davis, H.R. : Ezetimibe Potently Inhibits Cholesterol Absorption But Does Not Affect Acute Hepatic or Intestinal Cholesterol Synthesis in Rats. . British Journal of Pharmacology 138: 1459-1464, 2003.
  29. van Heek, M., Davis, H.R. : Pharmacology of Ezetimibe. Eur. Heart J. 4 (Suppl. J) J5-J8, 2002 (Dec).
  30. Altmann, S.W., Davis, H.R. , Yao, X., Laverty, M., Compton, D.S., Zhu, L., Crona, J.H., Caplen, M.A., Hoos, L.M., Tetzloff, G., Priestley, T., Burnett, D.A., Strader, C.D., Graziano, M.P.: The identification of intestinal Scavenger Receptor Class B, Type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochimica et Biophysica Acta 1580: 77-93, 2002.
  31. Burnett, D.A., Caplen, M.A., Browne, M.E., Khau, H., Altmann, S.W., Davis, H.R. , Clader, J.W.: Synthesis of Fluorescent Biochemical Tools Related to the 2-Azetidinone Class of Cholesterol Absorption Inhibitors. Bioorg Med Chem Letters 12: 315-318, 2002.
  32. Burnett, D.A., Caplen, M.A., Domalski, M.S., Browne, M.E., Davis, H.R. , Clader, J.W.: Synthesis of Iodinated Biochemical Tools Related to the 2-Azetidinone Class of Cholesterol Absorption Inhibitors. Bioorg Med Chem Letters 12: 311-314, 2002.
  33. Burnett, D.A., Davis, H.R. : Chapter 6. Recent advances in the science and treatment of atherosclerosis. Annual Reports in Medicinal Chemistry, Volume 36: 57-66, 2001.
  34. Davis, H.R. , Compton, D.S., Hoos, L., Tetzloff, G.: Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in Apo E knockout mice. Arterioscler. Thromb. Vasc. Biol. 21: 2032-2038, 2001.
  35. Vemulapalli, R., Kurowski, S., Salisbury, B., Parker, E., Davis H.: Melanotan-II as a modulator of erectile function in rabbits. British J.Pharm. 134: 1705-1710, 2001.
  36. van Heek, M., Farley, C., Compton, D.S., Hoos, L., Davis, H.R. : Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. British J.Pharm. 134: 409-417, 2001.
  37. Davis, H.R. , Pula, K., Alton, K.B., Burrier, R.E., Watkins, R.W.: The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor ezetimibe in combination with HMG CoA reductase inhibitors in dogs. Metabolism 50 (10): 1234-1241, 2001.
  38. van Heek, M., Austin, T.M., Farley, C., Cook, J.A., Tetzloff, G.G., Davis, H.R. : Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese, hyperinsulinemic hamsters. Diabetes 50:1330-1335, 2001.
  39. van Heek, M., Compton, D.S., Davis, H.R. : The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. European J.Pharm. 415: 79-84, 2001.
  40. Rosenblum, S.B., Huynh, T., Afonso, A. and Davis H.R. : Synthesis of 3-arylpropenyl, 3-arylpropynyl, and 3-arylpropyl 2-azetidinones as cholesterol absorption inhibitors: application of the palladium-catalysed arylation of alkenes and alkynes. Tetrahedron 56:5735-5742, 2000.
  41. van Heek, M., Farley, C., Compton, D.S., Hoos, L., Alton, K.B., Sybertz, E.J., and Davis, H.R. : Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. British Journal of Pharmacology 129: 1748-1754, 2000.
  42. Vaccaro, W.D., Sher, R., and Davis, H.R. : Carboxy-substituted 2-Azetidinones as cholesterol absorption inhibitors. Bioorg Med Chem Letters 8: 319-322, 1998.
  43. Vaccaro, W.D., Sher, R. and Davis, H.R. : Sugar substituted 2-azetidinones as cholesterol absorption inhibitors. Bioorg Med Chem Letters 8: 35-40, 1998.
  44. Vaccaro, W.D., Sher, R., and Davis, H.R. : 2-Azetidinone cholesterol absorption inhibitors: Increased potency by substitution of the C-4 phenyl ring. Bioorg Med Chem 6(9): 1429-1237, 1998.
  45. Wang, S., Ghibaudi, L., Hashemi, T., He, C., Strader, C., Bayne, M., Davis, H.R. , and Hwa, J.: The GalR2 galanin receptor mediates galanin-induced jejunal contraction, but not feeding behavior, in the rat: Differentiation of central and peripheral effects of receptor activation. FEBS Letters 434: 277-282, 1998.
  46. Rosenblum, S.B., Huynh, T., Davis H.R. , Yumibe, N., Clader, J., Afonso, A. and Burnett, D.: Discovery of SCH58235, a designed potent orally active inhibitor of cholesterol absorption. J. Med. Chem. 41(6):973-980, 1998
  47. Burnett, D.A., Caplen, M.A., Clader, J.W., Davis, H.R. , Alkoxy acid substituted B-lactams as cholesterol absorption inhibitors. Bioorganic & Medicinal Chemistry Letters.
  48. McKittrick, B.A., Ma, K., Huie, K., Yumibe, N., Davis, H.R. , Clader, J.W., Czarniecki, M. and McPhail, A.T.: Synthesis of C3 heteroatom substituted azetidinones that display potent cholesterol absorption inhibitory activity. J. Med. Chem. 41(5):752-759, 1998.
  49. Davis, H.R. , Mullins, D.E., Pines, J.M., Hoos, L.M., France, C.F., Compton, D.S., Graziano, M.P., Sybertz, E.J.,Strader, C.D., and Van Heek, M.: Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats. Obesity Research. 6 (2):147-156, 1998.
  50. Watkins, R.W., Cook, J., Pula,K., Grzelack, M., and Davis, H.R. : Glucagon-like Peptide-1 Amide-Induced Changes in Arterial Blood Pressure in Conscious Rats. Eur. J. Pharm. In revision.
  51. Van Heek, M., France, C.F., Compton, D.S., McLeod, R.L., Yumibe, N.P., Alton, K.B., Sybertz, E.J., and Davis, H.R. : In vivo mechanism-based discovery of a potent cholesterol absorption inhibitor (SCH58235) through the identification of the active metabolites of SCH48461. The Journal of Pharmacology and Experimental Therapeutics (JPET), 283: 157-163, 1997.
  52. Van Heek, M., Compton, D.S., France, C.F., Tedesco, R.P., Fawzi, A., Graziano, M.P., Sybertz, E.J.,Strader, C.D., and Davis, H.R. : Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J. Clinical Invest. 99(3): 385-390, 1997.
  53. Van Heek, M., Mullins, D.E., Wirth, M.A., Graziano, M.P., Fawzi, A., Compton, D.S., France, C.F., Hoos, L.M., Casale, R.L., Sybertz, E.J.,Strader, C.D., and Davis, H.R. : The relationship of tissue localization, distribution, and turnover to feeding after intraperitoneal 125I-leptin administration to ob/ob and db/db mice. Hormone and Metabolic Research. Experimental Endocrinology and Metabolism, 28: 653-658, 1996.
  54. Hwa, J., Fawzi, A., Graziano, M.P., Ghibaudi, L., Williams, P., Van Heek, M., Davis, H.R. , Rudinski, M., Sybertz, E.and Strader, C.D.: Leptin Increases Thermogenesis and Selectively Promotes Fat Metabolism in Ob/ob Mice. Am J Physiol. 272:R1204-R1209, 1997.
  55. Vaccaro, W., Amore, C., Berger, J.G., Burrier, R.E., Clader, J.W., Davis, H.R. , Domalski, M., Fevig, T., Salisbury, B. and Sher, R.: Inhibitors of acyl CoA: cholesterol acyltransferase. J.Med.Chem. 39:1704-1719, 1996.
  56. Vemulapalli, S., Watkins, R.W., Chintala, M., Davis, H.R. , Ahn, H., Fawzi, A., Tulshian, D., Chiu, P., Chatterjee, M., Lin, C., and Sybertz, E.J.: Antiplatelet and antiproliferative effects of SCH51866, a novel type I and typeV phosphodiesterase inhibitor. J. Cardiovascular Pharm. 28: 862-869, 1996.
  57. Clader, J.W., Burnett, D.A.,CaplenM.A., Domalski, M.S., Dugar, S., Vaccaro, W., Sher, R., Browne, M.E., Zhao, H., Burrier, R.E., Salisbury, B., and Davis, H.R. : 2-Azetidinone cholesterol absorption inhibitors : Structure-activity relationships on the heterocyclic nucleus. J.Med.Chem. 39(19): 3684-3693, 1996.
  58. Kirkup, M., Rizvi, R., Shankar, B.B., McCombie, S.W., Lin, S., Yumibe, N., Huie, K., Van Heek, M., Compton, D.S., and Davis, H.R. : SCH57939: Synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor. Bioorganic & Medicinal Chemistry Letters. 6(17): 2069-2072, 1996
  59. McKittrick, B.A., Ma, K., Dugar, S., Clader, J.W., Davis, H.R. , Czarniecki, M. and McPhail, A.T.: Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorption inhibitors. Bioorganic & Medicinal Chemistry Letters. 6(16): 1947-1950, 1996.
  60. Dugar, S., Yumibe, N., Clader, J.W., Vizziano, M., Huie, K., Van Heek, M., Compton, D.S., and Davis, H.R. : Metabolism and structure activity data based drug design: Discovery of (-) SCH53079 an analog of the potent cholesterol absorption inhibitor (-) SCH48461. Bioorganic & Medicinal Chemistry Letters 6 (11): 1271-1274, 1996.
  61. Dugar, S., Clader, J.W., ChanT-M., and Davis, H.R. : Substituted 2-Azaspiro[5.3]nonan-1-ones as potent cholesterol absorption inhibitors: Defining a binding conformation for SCH48461. J. Med Chem 38: 4875-4877, 1995.
  62. Dugar, S., Kirkup, M.P., Clader, J.W., Lin, S., Rizvi, R., Snow, M.E., Davis, H.R. , and McCombie, S.W.: Gamma-lactams as cholesterol absorption inhibitors: Homologs of the Beta-lactam cholesterol absorption inhibitor SCH48461. Bioorganic & Medicinal Chemistry Letters 5: 2947-2952, 1995.
  63. Dugar, S., Burrier, R.E., Davis, H.R. , and Salisbury, B.G.: Amides of piperidine, morpholine and piperazine substituted 1-phenylethylamines: Inhibitors of acyl CoA: cholesterol acyltransferase (ACAT) activity in vitro and in vivo. Bioorganic & Medicinal Chemistry 3(9): 1231-1236, 1995.
  64. Sybertz, E.J., Davis, H.R. , Van Heek, M., Burrier, R.E., Salisbury, B.G., Romano, M.T., Clader, J.W. and Burnett, D.A.: SCH48461, a novel inhibitor of cholesterol absorption. In: Atherosclerosis X, Eds. Woodford, F.P., Davignon, J. and Sniderman, A, Pub. Elsevier, pp. 311-315, 1995
  65. Clader, J.W., Berger, J.G., Burrier, R.E., Davis, H.R. , Domalski, M., Dugar, S., Kogan, T.P., Salisbury, B. and Vaccaro, W.: Substituted (1,2-Diarylethyl) amide acyl-CoA: cholesterol acyltransferase inhibitors: effect of polar groups on in vitro and in vivo activity. J.Med.Chem. 38(10):1600-1607, 1995.
  66. Salisbury, B.G., Davis, H.R. , Burrier, R.E., Burnett, D.A., Boykow, G., Caplen, M. A., Clemmons, A.L., Compton, D.S., Hoos, L.M., McGregor, D.G., Schnitzer- Polokoff, R., Smith, A.A., Weig, B.C., Zilli, D.L., Clader, J.W. and Sybertz, E.J.: Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH48461. Atherosclerosis 115:45-63, 1995
  67. Burrier, R.E., Smith, A.A., McGregor, D.G., Hoos, L.M., Zilli, D.L., and Davis, H.R. : The effect of Acyl CoA: Cholesterol Acyltransferase inhibition on the uptake, esterification, and secretion of cholesterol by the hamster small intestine. The Journal of Pharmacology and Experimental Therapeutics JPET 272:156-163, 1995.
  68. Mullins, D.E., Hamud, F., Reim, R., and Davis, H.R. : Inhibition of PDGF receptor binding and PDGF-stimulated biological activity in vitro and of intimal lesion formation in vivo by 2-bromomethyl-5-chlorobenzene sulfonylphthalimide. ArteriosclerThromb. 14:1047-1055, 1994.
  69. Burrier, R.E., Deren, S., McGreger, D.G., Hoos, L.M., Smith, A.A., and Davis, H.R. : Demonstration of a direct effect on hepatic acyl CoA:cholesterol acyl transferase (ACAT) activity by an orally administered enzyme inhibitor in the hamster. Biochemical Pharmacology 47(9):1545-1551, 1994.
  70. Burnett, D.A., Caplen, M.A., Davis, H.R. , Burrier, R.E., and Clader, J.W.: 2-Azetidinones as inhibitors of cholesterol absorption. J.Med.Chem. 37(12):1733-1736, 1994.
  71. Watkins, R.W., Pula,K., Cook, J., Hoos, L., McLeod, R., Prioli, N.A., and Davis, H.R. : N-Nitro-L-Arginine Methyl Ester does not effect ballon catheter-induced intimal hyperplasia in rats. Biochem. Biophys. Res. Com. 197(1):304-309, 1993.
  72. Schnitzer-Polokoff, R., Compton, D., Boykow, G., Davis, H.R. , Burrier, R.: Effects of acyl-CoA: cholesterol o-acyltransferase inhibition on cholesterol absorption and plasma lipoprotein composition in hamsters. Comp.Biochem. Physiol. 99A(4):665-670 1991.
  73. Elner, S.G., Elner, V.M., Pavilack, M.A., Davis, H.R. , Cornicelli, J.A., Yue, B.Y.J.T.: Human and monkey corneal endothelium expression of low-density lipoprotein receptors. American J. Ophthalmology 111:84-91, 1991.
  74. Rich, S., Miller, J.F., Charous, S., Davis, H.R. , Shanks, P., Glagov, S., Lands, W.E.M.: Development of atherosclerosis in genetically hyperlipidemic rabbits during chronic fish-oil ingestion. Arteriosclerosis 9:189-194, 1989.
  75. Davis, H.R. , Runyon-Hass, A., Zarins, C.K., Glagov, S.: An enzymatic mechanism for the synergistic effect of hypertension and hypercholesterolemia on atherogenesis.
  76. Elner, V.M., Elner, S.G., Huntinton, A.C., Davis, H.R. , Langloss, J.M., Hidayat, A.A.: Ophthalmic lesions of sinus histiocytosis with massive lymphadenopathy: Immunohistochemical and lectin staining of histocyte subpopulations.
  77. Lichtor, T., Davis, H.R. , Vesselinovitch, D., Wissler, R.W., Mullan, J.F.: Suppression of atherogenesis by nifedipine in the cholesterol-fed rhesus monkey, Appied Pathology, 7:8-18, 1989.
  78. Bassiouny, H.S., Davis, H.R. , Massawa, N., Gewertz, B.L., Glagov, S., Zarins, C.K.: Critical carotid stenoses: morphological and chemical similarity between symptomatic and asymptomatic plaques. J. Vascular Surgery, 9:202-212, 1989.
  79. Cozzi, P.J., Lyon, R.T., Davis, H.R. , Sylora, J., Glagov, S., Zarins, C.K.: Aortic wall metabolism in relation to susceptibility and resistance to experimental atherosclerosis. J. of Vascular Surgery, 7(5):706-714, 1988.
  80. Wissler, R.W., Davis, H.R. , Vesselinovitch, D., Podbielski, F.J. and Bridenstine, R.T. A preliminary report of acute and chronic studies of atherogenic related effects eicosapentaenoil acid-rich rations in rhesus monkeys. In: W.E.M. Lands (Ed.), Proceedings of the AOCS short course on polyunsaturated fatty acids and eicosanoids, Champaign, IL, 1987, pp. 66-69.
  81. Wissler, R.W., Davis, H.R. , Vesselinovitch, D.: Identification and characterization of cellular components of early atherosclerotic plaque. In: Atherosclerosis and heart disease: A multidisciplinary approach, AFPI Workshop, June 3-5, 1987.
  82. Davis, H.R. , Bridenstine, R.T., Vesselinovitch, D., Wissler, R.W.: Fish oil inhibits development of atherosclerosis in rhesus monkeys. Arteriosclerosis, 7(5):441-449, 1987.
  83. Lichter, T., Davis, H.R. Johns, L., Vesselinovitch, D., Wissler, R.W., Mullen, S.: The sympathetic nervous system and atherosclerosis. J. of neurosurgery, 67:906-914, 1987.
  84. Yue, B.Y., Elner, V.M., Elner, S.G. and Davis H.R. Lysosomal enzyme activities in cultured trabecular-mesh work cells. Exp. Eye Res., 44(6):891-897, 1987.
  85. Grande, J., Davis, H.R. , Bates, S., Mathews, M.B., Glagov, S.: An elastin growth substrate increases cholesteryl ester synthesis and induces foam cell formation by cultured aortic smooth muscle cells. Atherosclerosis, 68:87-93, 1987.
  86. Lyon, R.T., Runyon-Hass, A., Davis, H.R. , Glagov, S., Zarins, C.K.: Protection from atherosclerotic lesion formation by reducing artery wall motion. J. of Vascular Surgery, 5(1):59-67, 1987.
  87. Wissler, R.W., Vesselinovitch D., Davis, H.R. : Cellular components of the progressive atherosclerotic process. In: Atherosclerosis: Biology and Clinical Science, Eds., Olsson, Adams, C., Gresham, A. and Wissler, R.W., Pub. ChurchillLivingstone, U.K., 1987.
  88. Wissler, R.W., Vesselinovitch, D., Davis, H.R. , Yamada, T.: The composition of the evolving atherosclerotic plaque. In: Vascular Disease, Current Research and Clinical Applications, Ed. Strandness, D.E., Didisheim, P., Clowes, A.W., Watson, J.T., Pub. Grune and Stratton, Inc., Orlando, Florida, pp. 241-2565, 1987.
  89. Glagov, S., Zarins, C.K., Giddens, D.P., Davis, H.R. : Atherosclerosis: What is the nature of the plaque? In: Vascular Diseases, Current Research and Clinical Applications, Ed. Strandness, D.E., Didisheim, P., Clowes, A.W., J.T.Watson, Pub. Grune and Stratton, Inc., Orlando, Florida, pp. 15-33, 1987.
  90. Davis, H.R. , Glagov, S.: Lectin binding to distinguish cell types in fixed atherosclerotic arteries. Atherosclerosis, 61:193-203, 1986.
  91. Wissler, R.W., Vesselinovitch, D., Davis, H.R. , Lambert, P.H., Bekermeier, M.: A new way to look at atherosclerotic involvement of the artery wall and the functional effects. Annals of the N.Y.Academy of Sciences, 454:9-22, 1985.
  92. Davis, H.R. Glagov, S., Zarins C.K.: Role of acid lipase in cholesteryl ester accumulation during atherogenesis: Correlation of enzyme activity with acid lipase containing macrophages in rabbit and human lesions. Atherosclerosis, 55(2):205-215, 1985.
  93. Davis H.R. , Vesselinovitch, D., Wissler, R.W.: Histochemical detection and quantification of macrophages in rhesus and cynomolgus monkey atherosclerotic lesions. J.Histochem. Cytochem. 32(12):1319-1327, 1984.
  94. Davis, H.R. , Vesselinovitch, D., Wissler, R.W.: Reticuloendothelial system response to hyperlipidemia in rhesus and cynomolgus monkeys. J. Leukocyte Biol. 36:63-80, 1984.
  95. Davis H.R. , Wissler, R.W.: ApoproteinB quantification in rhesus and cynomolgus monkey atherosclerotic lesions. Atherosclerosis, 50:241-252, 1984.
  96. Elner, V.M., Hass, A.J., Davis, H.R. , Glagov, S.: An avidin-biotin peroxidase method for Fc receptors on macrophages isolated from and in sections of rat lung. J.Histochem. Cytochem. 31:1139-1141, 1983.
  97. Hass, A.J., Davis, H.R. , Elner, V.M., Glagov, S.: Identification of macrophages in sections of rabbit lung using acetoacetylated lipoproteins. J.Histochem. Cytochem. 31:1136-1138, 1983.
  98. Davis, H.R. : Comparative pathological study of atherosclerosis in two monkey species. Ph.D. Thesis. University of Chicago, 1982.